Answers are grounded in this paper and cite their sources.
BACKGROUND The COVID-19 pandemic catalyzed the adoption of digital technologies in health care. This study assesses a digital-first integrated care model for type 2 diabetes management in Western Sydney, using continuous glucose monitoring (CGM) and virtual Diabetes Case Conferences (DCC) involving the patient, general practitioner (GP), diabetes specialist, and diabetes educator at the same time. OBJECTIVE This study aims to assess the effectiveness of the innovative diabetes clinics in Western Sydney. METHODS In 2020, a total of 833 new patients with type 2 diabetes were seen at Western Sydney Diabetes (WSD) clinics. An early cohort of 103 patients was evaluated before and after participation in virtual DCC, incorporating CGM data analysis, digital educational resources, and remote consultations with a diabetes multidisciplinary team. Assessments were conducted at baseline and 3-4 months post DCC. RESULTS The integration of CGM and virtual consultations significantly improved glycemic control. Hemoglobin A1c (HbA1c) levels decreased notably from 9.6% to 8.2% (average reduction of 1.4%; 95% CI 1.03-1.82; P<.001). Time in range (TIR) as measured by CGM increased substantially from 46% to 73% (95% CI 20-32; P<.001), and the glucose management indicator (GMI) improved from 7.9% to 7% (average reduction of 0.9%; 95% CI 0.55-1.2; P<.001). Despite no significant change in the total daily insulin dose, the proportion of patients on insulin therapy rose from 27% to 39% (P<.001), indicating more targeted and effective diabetes management. CONCLUSIONS Our findings demonstrate the effectiveness of a digitally enabled integrated care model in managing type 2 diabetes. The use of CGM technology, complemented by virtual DCCs and digital educational tools, not only facilitated better disease management and patient engagement but also empowered primary care providers with advanced management capabilities. This digital approach addresses traditional barriers in diabetes care, highlighting the potential for scalable, technology-driven solutions in chronic disease management. CLINICALTRIAL
No takes yet. Share an insight, caveat, or question.
Mahfuza et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: